Amyloidosis and COVID-19: experience from an amyloid program in Canada.
Amyloid
COVID-19
Light-chain amyloidosis
SARS CoV2
Transthyretin amyloidosis
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
05
05
2022
accepted:
18
08
2022
pubmed:
27
8
2022
medline:
14
9
2022
entrez:
26
8
2022
Statut:
ppublish
Résumé
Severe acute respiratory syndrome coronavirus (SARS-CoV2) and associated COVID-19 infection continue to impact patients globally. Patients with underlying health conditions are at heightened risk of adverse outcomes from COVID-19; however, research involving patients with rare health conditions remains scarce. The amyloidoses are a rare grouping of protein deposition diseases. Light-chain and transthyretin amyloidosis are the most common disease forms, often present with systemic involvement of vital organs including the heart, nerves, kidneys, and GI tracts of affected individuals. The Amyloidosis Program of Calgary examined 152 ATTR patients and 103 AL patients analyzing rates of vaccination, COVID-19 testing, infection outcomes, influence referrals, and excess deaths. Results showed 15 total PCR-confirmed COVID-19 infections in the tested population of amyloid patients, with a higher frequency of infections among patient with AL compared to the ATTR cohort (26.2% vs 5.1%). Four patients (26.6%) required hospital admission for COVID-19 infection, 2 ATTR, and 2 AL patients. Of the confirmed cases, 1 (0.07%) unvaccinated ATTR patient died of a COVID-19 infection. An excess of deaths was found in both the ATTR and AL cohorts when comparing pre-pandemic years 2018 and 2019 to the pandemic years of 2020 and 2021. The finding suggests that amyloidosis patients are likely at a high risk for severe COVID-19 infection and mortality, especially those of advanced age, those on an active treatment with chemotherapy, and those with concomitant B-cell or plasma cell disorder. The impact of virtual healthcare visits and pandemic measures on the excess of deaths observed requires further research.
Identifiants
pubmed: 36028582
doi: 10.1007/s00277-022-04964-y
pii: 10.1007/s00277-022-04964-y
pmc: PMC9417080
doi:
Substances chimiques
Amyloid
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2307-2315Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Coronavirus disease 2019 (COVID-19) situation report-51. World Health Organization. March 11, 2020. Accessed April 15, 2022. 20200311-sitrep-51-covid-19.pdf (who.int)
WHO Coronavirus (COVID-19) Dashboard. World Health Organization. Accessed April 15, 2022. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
COVID-19 Alberta Statistics: interactive aggregate data on COVID-19 cases in Alberta. Government of Alberta. Updated April 4, 2022. Accessed April 15, 2022. COVID-19 Alberta statistics | alberta.ca
Beaumont AL, Vignes D, Sterpu R, et al. Factors associated with hospital admission and adverse outcome for COVID-19: role of social factors and medical care [published online ahead of print, 2022 Feb 13]. Infect Dis Now. 2022;S2666–9919(22)00032-X. https://doi.org/10.1016/j.idnow.2022.02.001
Fang X, Li S, Yu H et al (2020) Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY) 12(13):12493–12503. https://doi.org/10.18632/aging.103579
doi: 10.18632/aging.103579
Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349(6):583–596. https://doi.org/10.1056/NEJMra023144
doi: 10.1056/NEJMra023144
pubmed: 12904524
Benson MD, Buxbaum JN, Eisenberg DS et al (2020) Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 27(4):217–222. https://doi.org/10.1080/13506129.2020.1835263
doi: 10.1080/13506129.2020.1835263
pubmed: 33100054
Kastritis E, Wechalekar A, Schönland S, Sanchorawala V, Merlini G, Palladini G, Minnema M, Roussel M, Jaccard A, Hegenbart U, Kumar S, Cibeira MT, Blade J, Dimopoulos MA (2020) Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. Br J Haematol 190:346–357. https://doi.org/10.1111/bjh.16898
doi: 10.1111/bjh.16898
pubmed: 32480420
pmcid: 7300844
Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720
doi: 10.1056/NEJMoa2002032
Brannagan TH 3rd, Auer-Grumbach M, Berk JL et al (2021) ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis 16(1):204
doi: 10.1186/s13023-021-01834-0
Broom A, Kenny K, Page A, Cort N, Lipp ES, Tan AC, Ashley DM, Walsh KM, Khasraw M (2020) The paradoxical effects of COVID-19 on cancer care: current context and potential lasting impacts. Clin Cancer Res. 26(22):5809–5813. https://doi.org/10.1158/1078-0432.CCR-20-2989
doi: 10.1158/1078-0432.CCR-20-2989
pubmed: 32816894
Vijenthira A, Gong IY, Fox TA et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136(25):2881–2892. https://doi.org/10.1182/blood.2020008824
doi: 10.1182/blood.2020008824
pubmed: 33113551
pmcid: 7746126
Buske C, Dreyling M, Alvarez-Larrán A et al (2022) Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus. ESMO Open 7(2):100403. https://doi.org/10.1016/j.esmoop.2022.100403
doi: 10.1016/j.esmoop.2022.100403
pubmed: 35272130
pmcid: 8795783
Falk RH, Comenzo RL, Skinner M (1997) The systemic amyloidoses. N Engl J Med 337(13):898–909
doi: 10.1056/NEJM199709253371306
Schiller Salton N, Szwarcwort M, Tzoran I et al (2021) Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis. Am J Hematol 96(12):E475–E478. https://doi.org/10.1002/ajh.26373
doi: 10.1002/ajh.26373
pubmed: 34622495
pmcid: 8646558
Griffiths EA, Segal BH (2021) Immune responses to COVID-19 vaccines in patients with cancer: promising results and a note of caution. Cancer Cell 39(8):1045–1047. https://doi.org/10.1016/j.ccell.2021.07.001
doi: 10.1016/j.ccell.2021.07.001
pubmed: 34242573
pmcid: 8253695
Chen L, Li X, Chen M, Feng Yi, Xiong C (2020) The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res 116(6):1097–1100. https://doi.org/10.1093/cvr/cvaa078
doi: 10.1093/cvr/cvaa078
pubmed: 32227090
Xie Y, Xu E, Bowe B et al (2022) Long-term cardiovascular outcomes of COVID-19. Nat Med 28:583–590. https://doi.org/10.1038/s41591-022-01689-3
doi: 10.1038/s41591-022-01689-3
pubmed: 35132265
pmcid: 8938267
Maringe Camille, Spicer James, Morris Melanie et al (2021) The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: A national, population-based, modelling study. Lancet Oncol 21(8):1023–1034. https://doi.org/10.1016/s1470-2045(20)30388-0
doi: 10.1016/s1470-2045(20)30388-0
Sud A, Jones ME, Broggio J et al (2020) Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 31(8):1065–1074. https://doi.org/10.1016/j.annonc.2020.05.00
doi: 10.1016/j.annonc.2020.05.00
pubmed: 32442581
McCausland KL, White MK, Guthrie SD et al (2018) Light Chain (AL) Amyloidosis: the journey to diagnosis. Patient 11(2):207–216. https://doi.org/10.1007/s40271-017-0273-5
doi: 10.1007/s40271-017-0273-5
pubmed: 28808991
Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM et al (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 79(7):1817–22
doi: 10.1182/blood.V79.7.1817.1817
Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD et al (2013) Systemic amyloidosis in England: an epidemiological study. Br J Haematol 161(4):525–532
doi: 10.1111/bjh.12286
Winburn I, Ishii T, Sumikawa T, Togo K, Yasunaga H (2019) Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan. Cardiol Ther 8(2):297–316. https://doi.org/10.1007/s40119-019-0142-5
doi: 10.1007/s40119-019-0142-5
pubmed: 31376091
pmcid: 6828925